JAMES WELSH to Ipilimumab
This is a "connection" page, showing publications JAMES WELSH has written about Ipilimumab.
Connection Strength
1.304
-
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909.
Score: 0.479
-
Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies. J Immunother Cancer. 2024 Oct 09; 12(10).
Score: 0.169
-
Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease. Radiother Oncol. 2023 06; 183:109618.
Score: 0.151
-
Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials. Int J Radiat Oncol Biol Phys. 2018 08 01; 101(5):1141-1148.
Score: 0.108
-
Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol. 2017 10; 125(1):80-88.
Score: 0.103
-
Phase I Trial: SABR and Ipilimumab-Response. Clin Cancer Res. 2017 01 01; 23(1):321.
Score: 0.098
-
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396.
Score: 0.097
-
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. J Immunother Cancer. 2023 07; 11(7).
Score: 0.039
-
Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma. Gynecol Oncol. 2021 06; 161(3):645-652.
Score: 0.033
-
Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy. Immunotherapy. 2018 08; 10(10):851-0.
Score: 0.027